-
Takeda's global boost Takeda chronicles The market value for Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) has fallen from a peak in local currency of ¥7.4 trillion ($60.9 billion) in June 2007 to ¥3 trillion ($37.3 …
Published on 5/23/2011
-
Takeda's global boost Takeda's trajectory Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said the acquisition of Nycomed will add 30% to its revenue by fiscal year ending March 31, 2014 (FY13), raising its expectation …
Published on 5/23/2011
-
Alkermes' acquisition of Elan's EDT unit goes beyond quelling the competitive risk to Risperdal Consta, revamping its balance sheet and product portfolio to become a commercially minded company with its own products.
Published on 5/16/2011
-
Full Reset at Alkermes Revenue diversification By acquiring Elan Drug Technologies from Elan Corp. plc (NYSE:ELN), Alkermes Inc. (NASDAQ:ALKS) becomes less reliant on its Risperdal Consta risperidone revenue stream …
Published on 5/16/2011
-
Full Reset at Alkermes Alkermes-EDT pipeline The acquisition of Elan Drug Technologies adds at least two pain programs and one cancer compound to the clinical pipeline at Alkermes Inc. (NASDAQ:ALKS). EDT or its …
Published on 5/16/2011
-
Yakult: Special at Home Yakult Honsha deals Cancer deals announced by Yakult Honsha Ltd. (Tokyo:2267); Source: BCIQ: BioCentury Online Intelligence Date Partner Deal description Status of in-licensed program …
Published on 5/16/2011
-
With three in-licensing deals this year, Yakult Honsha has boosted its plan to build one of the largest specialty cancer businesses in Japan, with a target of Y100 billion in annual revenues by 2020.
Published on 5/16/2011
-
Cephalon checks all the boxes in Teva's push to reach $31 billion in sales by 2015, but the Israeli pharma still needs more acquisitions, execution in emerging markets and cost synergies.
Published on 5/9/2011
-
Teva's balancing act Teva's branded pipeline Cephalon Inc. (NASDAQ:CEPH) has 11 compounds in Phase II and Phase III testing - plus eight marketed drugs. This will bring the total number of products in late-stage …
Published on 5/9/2011
-
Teva's balancing act Teva's income trajectory Prior to the deal with Cephalon Inc. (NASDAQ:CEPH), the Street was expecting non-GAAP net income for Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) of $6 billion in …
Published on 5/9/2011
-
Teva's balancing act Teva's sales trajectory Teva Pharmaceutical Indutries Ltd. (NASDAQ:TEVA) will need to do more than acquire Cephalon Inc. (NASDAQ:CEPH) to meet its goal of reaching $31 billion in revenues in …
Published on 5/9/2011
-
A CATT in the hat tale CATT efficacy CATT randomized patients with advanced macular degeneration into four groups: Lucentis ranibuzimab monthly or as-needed (pro re nata), and Avastin bevacizumab monthly or PRN. …
Published on 5/2/2011
-
A CATT in the hat tale CATT trap Although CATT compared only two drugs manufactured by Genentech Inc., it could have an important effect on the development of future drugs for advanced macular degeneration and …
Published on 5/2/2011
-
A CATT in the hat tale Lucentis sales trajectory Sales of Lucentis ranibizumab have grown to $2.9 billion in 2010 since the drug was approved for age-related macular degeneration in the U.S. in June 2006 and the EU …
Published on 5/2/2011
-
A CATT in the hat tale AMD comps Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Bayer AG (Xetra:BAY) hope to offer their VEGF Trap-Eye aflibercept ophthalmic solution as a new competitor with less frequent dosing …
Published on 5/2/2011
-
CATT was not powered to measure safety, and investigators say the statistically higher SAE rate for Avastin could be a fluke. Genentech is pulling out its own epidemiological data to suggest otherwise.
Published on 5/2/2011
-
Clinicians responding to the CATT study confirm that economics, not medicine, is driving decisions to treat AMD patients with Avastin, while they could make a case for Lucentis if price weren't a factor.
Published on 5/2/2011
-
Supercharging Astex Astex-SuperGen pipeline Astex Pharmaceuticals Inc., which is being formed by the merger of Astex Therapeutics Ltd. and SuperGen Inc., will have one marketed drug and seven compounds in clinical …
Published on 4/18/2011
-
SuperGen and Astex hope the combination of SuperGen's cash and Astex's pipeline and drug discovery technology will create a mid-tier cancer company.
Published on 4/18/2011
-
If Cephalon chooses to keep half the company Valeant doesn't want, the biotech will have to convince shareholders they are better off holding a cancer portfolio with three candidates with first-in-class potential.
Published on 4/4/2011
-
Half-A-Loaf Dilemma Cephalon's cancer pipeline Cephalon Inc. (NASDAQ:CEPH) has one marketed cancer drug, Treanda bendamustine, and at least 11 other cancer compounds, including four from the planned acquisitions of …
Published on 4/4/2011
-
Global health players say Tachi Yamada's successor at the Gates foundation needs to set priorities for an increasingly expensive pipeline, make the organization less opaque, and engage innovators in the biotech industry…
Published on 3/28/2011
-
Gates after Yamada Blog transparency Although the Bill and Melinda Gates Foundation keeps much of its activities cloaked, it does invest heavily in communications. In 2009, the foundation donated more than $77 …
Published on 3/28/2011
-
Gates after Yamada Gates grants to PDPs The Bill and Melinda Gates Foundation channels about half of its R&D funding for neglected diseases into product development partnerships (PDPs). These not-for-profit …
Published on 3/28/2011
-
Gates after Yamada PDP products Work at five product development partnerships funded in part by the Bill and Melina Gates Foundation has yielded two approved drugs - paromomycin, a repurposed antibiotic first …
Published on 3/28/2011